Trial watch: Oncolytic viruses for cancer therapy

Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Philippe Erbs, Jean Marc Limacher, Xavier Preville, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

99 Citaten (Scopus)

Samenvatting

Oncolytic viruses are natural or genetically modified viral species that selectively infect and kill neoplastic cells. Such an innate or exogenously conferred specificity has generated considerable interest around the possibility to employ oncolytic viruses as highly targeted agents that would mediate cancer cell-autonomous anticancer effects. Accumulating evidence, however, suggests that the therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect, but strongly relies on the induction of an endogenous immune response against transformed cells. In line with this notion, superior anticancer effects are being observed when oncolytic viruses are engineered to express (or co-administered with) immunostimulatory molecules. Although multiple studies have shown that oncolytic viruses are well tolerated by cancer patients, the full-blown therapeutic potential of oncolytic virotherapy, especially when implemented in the absence of immunostimulatory interventions, remains unclear. Here, we cover the latest advances in this active area of translational investigation, summarizing high-impact studies that have been published during the last 12 months and discussing clinical trials that have been initiated in the same period to assess the therapeutic potential of oncolytic virotherapy in oncological indications.

Originele taal-2Engels
Artikelnummere28694
TijdschriftOncoImmunology
Volume3
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - 2014
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Trial watch: Oncolytic viruses for cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit